Primary biliary cholangitis (PBC) is an autoimmune, cholestatic, chronic liver disease that ultimately progresses towards cirrhosis and liver failure if untreated. While ursodeoxycholic acid has been established as standard of care for PBC in the last few decades, significant advances in second-line treatment options have recently been made and new therapeutic developments are currently under evaluation. The purpose of this article is to provide the clinician with an overview of the current treatment options and future opportunities for patients with PBC.
Introduction
Primary biliary cholangitis (formerly termed primary biliary cirrhosis, PBC) is a rare disease (occurring in less than 1/2,000) mainly diagnosed in women. It is characterised by an autoimmune and inflammatory process targeting the interlobular bile ducts. Without treatment the disease generally progresses to cirrhosis and liver failure over a period of 10 to 20 years. In the eighties, liver transplantation was the only therapeutic resource for patients with PBC. A major landmark in the history of PBC was the introduction of ursodeoxycholic acid (UDCA) as an effective therapy. After many years of controversy, there is now a consensus to accept UDCA as the standard therapy. UDCA has been shown to extend transplantationfree survival, especially when started early in the course of the disease. [1] [2] [3] [4] The severity of PBC varies widely, young patients (less than 40-years old at onset) tend to progress more rapidly towards cirrhosis. The notion of an optimal biochemical response to UDCA therapy has been an important step towards assessing the severity of the disease and stratifying patients according to their risk of progressing towards liver failure. [5] [6] [7] [8] [9] About 30% to 40% of patients will not have an optimal biochemical response to UDCA. These patients exhibit more rapid disease progression than those with normalisation of serum alkaline phosphatase (ALP), aminotransferases and bilirubin. In a metaanalysis of 4,845 patients with PBC, the strongest predictors of death or liver transplantation were ALP levels more than 1.5-3x the upper limit of normal range and abnormal serum bilirubin. 10 These markers are now considered the gold standard of surrogate biochemical endpoints for clinical trials of novel therapies.
From pathophysiology to therapeutic opportunities
Despite relentless efforts to understand the autoimmune pathogenesis of PBC, to date, no potentially effective new immunotherapies have emerged. PBC is characterised by multilineage immune dysregulation, which is related to the loss of tolerance to the E2 component of the mitochondrial oxo-dehydrogenase pathway (mainly PDC E2). As in other autoimmune diseases, loss of peripheral tolerance might result from several non-mutually exclusive mechanisms involving predisposing genes, epigenetic changes, gender, chemicals, infections, molecular mimicry, tissue damage and inflammation.
Cholangiocytes as culprit and victim in the initiation and progression of PBC A milestone in the pathophysiology of PBC was the discovery of defective AE2 [SLC4A2] expression and biliary HCO 3 − secretion in patients with PBC, and its reversal by UDCA therapy. 11, 12 According to the bicarbonate « umbrella » theory, defective AE2 expression and reduced biliary bicarbonates might be responsible for the enhanced susceptibility of cholangiocytes to damage from biliary bile acids. 13 In addition to the lack of a bicarbonate protective barrier, the reduced alkalinity of bile in PBC might impair the physiological protective function of biliary ALP against danger/ pathogen-associated molecular pattern-induced biliary inflammation and stress. 14 and directly targets both AE2 and type III inositol 1,4,5-triphosphate receptor. MiR-506 induces downregulation of biliary and epithelial markers together with upregulation of mesenchymal, proinflammatory and profibrotic markers, as well as increasing oxidative and endoplasmic stress, and sensitising cholangiocytes to apoptosis. 15, 16 Further evidence suggests that senescence, dysregulated autophagy and apoptosis are among cholangiocytes' responses to oxidative stress and injury in PBC. 17 All these modes of response are associated with abnormal expression and presentation of mitochondrial antigens to immune cells. Indeed, these cholangiocyte responses might act as a downstream amplifying mechanism in the autoimmune process. 18 In brief, the combination of genetic susceptibility, abnormal adaptive responses to cholangiocyte injury, and epigenetic alterations may contribute to disease initiation and progression. According to current knowledge, protection of cholangiocytes by drugs (mainly UDCA, 24-norUCDA, 19 Farnesoid X 20 Finally, liver fibrosis in PBC results from both cholangiocellular and hepatocellular injury. 21 In this setting, the fibrogenic process appears to be related to complex interactions between immune/ inflammatory mechanisms, cytokine networks and the derangement of homeostasis between epithelial and mesenchymal cells, which could explain the current lack of efficacious antifibrotic drugs.
22,23
Current landscape of PBC therapies Open-label extension studies were able to show that 4-year UDCA therapy was associated with a lower probability of death or LT compared to a 2-year delay in UDCA introduction. 25, 34 After contradictory meta-analyses and extensive debates, UDCA has been recognised to slow disease progression and to reduce mortality and the need for LT, this effect being more significant when UDCA is started at early stages of disease and is continued for life. 4, 35 In clinical practice, UDCA therapy is associated with an excellent tolerability profile. Definitive discontinuation due to digestive adverse effects (diarrhoea, abdominal discomfort) is reported in less than 5% of patients.
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Second-line treatment options
Obeticholic acid
After UDCA, obeticholic acid (OCA) was the second drug to successfully meet the primary endpoint of a large placebo-controlled phase III trial in PBC. This goal was achieved both in patients with incomplete response or intolerance to UDCA and in UDCA-naive patients. 37, 38 OCA is a synthetic bile acid derivative with a high affinity for FXR, a nuclear receptor that closely regulates bile acid synthesis and secretion, and has been shown to mediate anti-inflammatory and antifibrotic effects. 39, 40 OCA is the first FXR-selective agonist approved as a therapeutic product in humans. OCA was conditionally approved by the US and EU regulatory authorities in 2016 for the treatment of PBC in patients with incomplete response or intolerance to UDCA. This approval, based on the results of the POISE study, a 1-year placebo-controlled trial with an extended 1-year open-label extension (OLE) period, is conditional on further evaluation in an ongoing phase IV trial (COBALT) to determine if the biochemical benefits associated with OCA therapy will have a direct impact on clinical outcomes/ quality of life in patients with PBC. 37 The characteristics of the POISE study are summarised in Table 1 . Inclusion criteria included a suboptimal biochemical response (i.e. ALP level ≥1.67x ULN or abnormal level of total bilirubin, but <2 mg/dl, after 1 year of UDCA) or intolerance to UDCA. A total of 216 patients were randomly assigned to OCA at a 10 mg daily dose (10 mg group), OCA at a dose of 5 mg with adjustment to 10 mg if applicable after 6 months (5-10 mg group), or placebo. In total, 93% of patients received UDCA (13-15 mg/kg/d) as background therapy. The primary outcome was an ALP level <1.67x ULN with a drop of ≥15% from baseline, and a normal bilirubin level. It occurred in 46% of patients in the 5-10 mg group, 47% in the 10 mg group, and 10% in the placebo group (p <0.001 for both comparisons). Compared to placebo, OCA was associated with a significant reduction in serum levels of ALP and total bilirubin (approximately -35% and -8%, respectively, from baseline to month 12). The levels of gamma-glutamyltransferase (GGT), alanine aminotransferase (ALT), aspartate aminotransferase (AST), conjugated bilirubin, and total bile acid also decreased significantly in each OCA group compared to placebo. Changes in non-invasive measures of liver fibrosis, including liver stiffness assessed by transient elastography and enhanced liver fibrosis (ELF™) score, did not differ significantly between either OCA group or the placebo group at 12 months. Pruritus was the most common adverse event reported during the double-blind phase of the study. It was 1.5-2-fold more common with OCA than with placebo, occurring in up to 68% of patients treated with OCA compared to 38% of patients receiving placebo. In the 5-10 mg arm, pruritus worsened in patients with pre-existing pruritus, but not in the patients without pruritus at baseline. The incidence and intensity of pruritus, and the rate of treatment discontinuation due to pruritus were consistently higher in the 10 mg group than in the 5-10 mg group. However, mainly Review as a result of OCA dose reductions, changes in pruritus scores tended to decrease over time with no significant difference observed at 12 months between either OCA group and the placebo group. The rate of serious adverse events was 16% in the 5-10 mg group, 11% in the 10 mg group, and 4% in the placebo group. The results and safety profile observed during the 12-month OLE period were consistent with those reported during the double-blind phase of the trial. Durable responses in the main serum markers of cholestasis were reported through 48 months of the OLE study in both patients treated with OCA from the double-blind phase and those initially treated with placebo then switched to OCA. 41 In this long-term OLE study, pruritus was the most common side effect of OCA (reported in 77% of patients), but discontinuation due to pruritus was reported in only 4% of patients. In a POISE substudy, the effect of 3-year OCA therapy on liver fibrosis progression was assessed in 13 patients with paired liver biopsies. 42 In this small population, histological fibrosis stage only worsened in 2 (15%) patients, suggesting that OCA may slow fibrosis progression in patients with high-risk PBC.
Fibrates
Bezafibrate is the third treatment, after UDCA and OCA, to have shown clear beneficial effects in a large, well-powered, placebo-controlled trial in PBC. 43 Fibrates have been recognised since the 1960s as lipid lowering agents. They are potent agonists of the PPAR-α, a transcription factor involved in fatty acid catabolism and inflammatory response. Some fibrates, such as bezafibrate, further exhibit additional affinities for PPAR-δ and PPAR-γ, the other 2 isoforms of PPARs involved in energy metabolism and inflammatory processes. 44 Fibrates are also known to repress bile acid synthesis in the liver and to increase phospholipid excretion into the bile. 45, 46 In 1999, Iwasaki et al. were the first to report an improvement of the biological parameters of PBC, including ALP, GGT and IgM serum levels, with bezafibrate. 47 This observation was subsequently confirmed by numerous small, unblinded studies, first conducted in Japan, then replicated in Western countries, either with bezafibrate or with fenofibrate. [48] [49] [50] [51] [52] [53] The BEZURSO study (bezafibrate in combination with ursodeoxycholic acid in primary biliary cholangitis, NCT01654731) is the first and currently the only available placebo-controlled phase III trial aimed to assess the efficacy and safety of a fibrate in PBC. 43 The characteristics of this trial are summarised in Table 1 , alongside those of the POISE study. The BEZURSO study randomly assigned 100 patients who had an inadequate biochemical response to UDCA based on the Paris-2 criteria (i.e. ALP or AST levels >1.5x ULN, or elevated total bilirubin) to receive bezafibrate at a daily dose of 400 mg (50 patients), or placebo (50 patients), in addition to continued treatment with UDCA (13-15 mg/kg/d) for 24 months. The primary endpoint, defined as normal levels of bilirubin, ALP, aminotransferases, albumin, and prothrombin index (a derived measure of prothrombin time) at 24 months, was achieved in 31% of patients in the bezafibrate group and 0% in the placebo group (p <0.001). At 24 months, normal levels of ALP were observed in 67% of patients in the bezafibrate group and in 2% in the placebo group (p <0.001). Changes in total bilirubin, ALP, GGT, and aminotransferases were consistent with the result of the primary endpoint, as were the parallel changes in pruritus, fatigue, and non-invasive markers of liver fibrosis, including liver stiffness measurement and ELF score. Reduction in pruritus intensity, which was reported in previous studies, 45, 51 did not correlate with serum measures of autotaxin, a lysophospholipase previously shown to play a role in the pathogenesis of cholestatic pruritus. 54 Serum IgM levels decreased by 21% in the bezafibrate group and only 2% in the placebo group, but the difference did not reach the level of significance. The C4 bile acid precursor, a serum marker of bile acid synthesis, significantly decreased with bezafibrate, in parallel with the circulating fraction of endogenous bile acids. Like the POISE study, the BEZURSO study was not sufficiently powered to assess longterm clinical outcomes. The incidence of liverrelated complications at 24 months did not differ between groups (2 clinical events in each group, no death). The overall incidence rate of serious or nonserious adverse events did not differ between groups. Myalgia was more frequently observed in the bezafibrate group than in the placebo group (20% vs. 10%, respectively) but the difference was not significant. Bezafibrate was associated with a significant increase in serum creatinine level of 5% at 24 months, a well-known class effect of fibrates with no long-term impact on renal function. 55 Patients with features of portal hypertension or high ALP levels at baseline were less likely to respond to bezafibrate and to meet the primary endpoint. The application of the GLOBE and UK-PBC risk scores showed significantly lower projected mortality or need for LT at 5, 10, and 15 years in the bezafibrate group than in the placebo group. 56 Mortality or need for LT was predicted to increase by 15%-25% with placebo and to decrease by 30%-40% with bezafibrate. At the end of study, the differences in estimated 15-year outcomes between bezafibrate and placebo groups were −57% (95% CI −77% to −36%) with the UK-PBC score and −46% (95% CI −65% to −27%) with the GLOBE score.
Budesonide
Historically, budesonide was the first second-line treatment in PBC to show promising results in association with UDCA. 57, 58 Recent data, however, have been somewhat disappointing. 59 Budesonide is a non-halogenated corticosteroid with potent dual agonism for the glucocorticoid and xenobiotic pregnane X receptors (PXR), which exhibits a high (90%) first-pass effect through the liver when administered orally, thus limiting systemic bioavailability and related side effects. 60 The latter property is of specific relevance when considering the high risk of osteoporosis in women with PBC. Importantly, budesonide is inadvisable in cirrhotic patients in whom its first-pass effect is impaired, exposing them to significantly higher plasma concentrations and increased risk of systemic side effects. Oral budesonide is presently a licensed indication for patients with Crohn's disease, ulcerative colitis and autoimmune hepatitis. The first 2 randomised controlled trials of budesonide in PBC, one of which was unblinded, led to the same observation that at least 2 years of budesonide (6 mg/d) in association with UDCA (13-15 mg/kg/d) was associated with a significant improvement in histological activity and fibrosis scores, thus suggesting that budesonide can slow PBC progression. 57, 58 Budesonide was also shown to improve serum levels of ALP, aminotransferases, and IgM significantly, indicating that it was able to improve both cholestatic and immunological features of the disease. 57, 61 However, it should be noted that neither of these first 2 controlled trials was based on targeted at-risk populations. In a recent double-blind, placebo-controlled, still unpublished trial, 62 non-cirrhotic patients with PBC and an incomplete biochemical response to UDCA (defined by an ALP level >1.5x ULN) and a liver biopsy compatible with PBC and showing inflammatory activity within 6 months prior to baseline, were randomly assigned 2:1 to oral budesonide 9 mg/d (n = 40) or placebo (n = 22), with continued UDCA (12-16 mg/kg/d), for 36 months. 59 Adjusting the dose of budesonide down to 3 mg/d was allowed in patients with normal AST levels. Not all patients had a control liver biopsy (n = 43) or completed 3 years of treatment (n = 29). The primary endpoint, an improvement of ≥3 points in Ishak inflammatory activity score or no inflammation and no progression of fibrosis stage, did not differ between groups (43% in the budesonide group vs. 29% in the placebo group; p = 0.225), but the proportion of patients with serum ALP levels <1.67x ULN and a ≥15% drop from baseline and normal bilirubin was significantly higher in the budesonide group than in the placebo group at 12, 24, and 36 months (40% vs. 18%, 45% vs. 18%, and 43% vs. 23%, respectively; p <0.05 for each comparison). Adverse events were reported in a similar number of patients across groups. Adverse drug reactions were reported for 24 patients (60%) in the budesonide-and 8 patients (36%) in the placebo group. Budesonide was associated with significantly reduced serum cortisol concentration and lumbar spine bone density. In summary, while this latter study was negative with respect to the primary histological endpoint, clinically meaningful improvements in biochemical markers of disease activity were apparent and tolerability was consistent with prior clinical experience. Since studies using liver histology in PBC are challenging to achieve, a lack of power may explain these contrasting results. Accordingly, budesonide should still be considered as a potentially interesting candidate for second-line therapies in PBC.
Treatment algorithm
An inadequate biochemical response to UDCA is one of the strongest determinants of clinical outcomes in PBC. 5, 10 Therefore, it has been recommended that second-line therapy be considered specifically in the patients who experience such an incomplete response (Fig. 1) . 1, 2 The criteria used to define suboptimal response to UDCA (Paris-2, Toronto, GLOBE, Barcelona, etc.) can differ among teams and practitioners provided that they include both ALP and bilirubin levels. The European Association for the Study of the Liver recommends considering an ALP level >1.5x ULN or abnormal levels of total (and conjugated) bilirubin as biochemical thresholds above which second-line treatment or inclusion in clinical trials should be considered. 1 It is expected that more stringent criteria will be used in the future, as complete normalisation of ALP has been shown to provide additive value in predicting outcomes. 62 Advanced disease stage or progressive increase in liver stiffness, 2 other major predictors of clinical outcomes in PBC, are not currently taken into account in decisionmaking, but probably should be. 63 To date, OCA and bezafibrate (fenofibrate by extension) are the 2 drugs that should be considered first for secondline therapy in PBC, as both of them have proven successful in properly powered phase III trials and selected high-risk patients. 37, 43 Available data on fenofibrate suggest that beneficial effects comparable to those of bezafibrate can be expected with this drug, making it particularly attractive in countries in which bezafibrate is not available like in the US. 64, 65 While the use of fibrates in Western countries is still off-label for PBC, OCA benefits from a conditional approval by US and EU authorities. However, without regard to any regulatory and price considerations and in the absence of comparative studies, the choice between OCA and fibrates must rely on several parameters, among which are the local availability of the drug, the presence and intensity of pre-treatment pruritus, the presence and intensity of pre-treatment myalgia, the presence of pre-treatment renal dysfunction or dyslipidaemia, and the physician's own experience and confidence.
Therapeutic perspectives in the near future
A number of other options are currently under investigation for the treatment of non-responders to UDCA, with or without OCA or fibrates. Generally speaking and as already discussed, therapeutic opportunities in PBC are offered by targeting the so-called "upstream" immune response, "midstream" biliary injury leading to cholestasis and "downstream" fibrotic processes. 66 Novel therapeutic approaches target mainly cholestasis (which has a central role in disease progression) but a number of these primarily anti-cholestatic agents have multiple potential targets including anti-inflammatory, antifibrotic, immunomodulatory and metabolic effects. No single agent will be universally effective, so individualisation of therapy and smart combinations are likely to be required in the future. Stratification and timing of therapy are crucial. Nevertheless, we are approaching promising times for patients with PBC, provided that the off-target effects of these novel drugs are mild. The following paragraphs provide an overview of the most advanced therapeutic candidates under evaluation (the main available results are summarised in Table 2 ). Initial staging of PBC should preferably be based on non-invasive measures including total bilirubin, ALP, aminotransferases, albumin, platelet count, liver stiffness measurement, and liver ultrasound. All patients must be treated with UDCA as a first-line treatment. Intolerance to UDCA (diarrhoea, stomach burns) may occur rarely (5%). Alternative options (OCA or fibrates) should then be considered. Assessment of biochemical response to UDCA is typically performed at 12 months of UDCA, but earlier evaluation after as few as 6 months of UDCA therapy may be proposed in patients with the most severe or symptomatic (pruritus) disease. The response criteria used must include ALP and bilirubin levels (Paris-2, Toronto, GLOBE, etc.). Abnormal levels of total and conjugated bilirubin or ALP level >1.5x ULN are minimal thresholds above which secondline therapies should be considered. Patients with adequate biochemical response to UDCA can be kept on UDCA monotherapy. Advanced-stage responders or those with persisting abnormal ALP might be considered for second-line therapies. In poor biochemical responders, liver biopsy should be considered when AIH-PBC variant or any other hepatic comorbidity is suspected. Addition of corticosteroids (including budesonide) is recommended in patients with AIH-PBC variant. Patients with non-regressive jaundice (bilirubin >5 mg/dl) or features of advanced cirrhosis (Child-Pugh B-C) should be referred for liver transplant. All remaining poor responders to UDCA should be considered for second-line therapies (i.e. OCA or fibrates) in addition to continued UDCA. Fibrates should be preferred in patients with pruritus. Second-line therapies could be switched in case of poor tolerance (pruritus for OCA; myalgia for fibrates) or combined in case of insufficient response. AIH, autoimmune hepatitis; ALP, alkaline phosphatase; OCA, obeticholic acid; PBC, primary biliary cholangitis; UDCA, ursodeoxycholic acid; ULN, upper limit of normal.
Immunological agents
date (at least when used in a non-stratified manner). Indeed, these agents are most likely to be effective in early disease, even before it is clear that the patient is at high risk of progression. As a result, appropriate timely design of clinical trials with immunomodulatory therapy is a challenge. Recent trials of immunologic agents have included rituximab and ustekinumab. Rituximab was the first biologic agent tested in PBC. Rituximab is a B-cell-depleting monoclonal antibody targeting the CD20 antigen. An initial open-label study, enrolling 6 patients, demonstrated a significant reduction in ALP up to 36 months after 2 doses of 1,000 mg (separated by 2 weeks). 67 However, a subsequent open-label study, including 14 patients, demonstrated only a mild improvement in liver tests (although pruritus decreased in 60%), 68 and a phase II randomised controlled trial with improvement in fatigue as the primary outcome failed to demonstrate efficacy at 12 months. 69 The overall conclusion is that rituximab has limited efficacy in PBC and is not recommended despite a good short-term safety profile.
Because of genetic studies suggesting the importance of the IL-12 pathway, ustekinumab, a monoclonal antibody targeting IL-12 and IL-23 has been investigated in an open-label trial of 20 patients treated for 20 weeks. Only a modest decrease in ALP was observed (-12% at week 28) and the initially planned double-blind study was not initiated. 70 Other immunologic agents are under investigation and include modulation of the cytotoxic T-lymphocyte associated protein 4 (CTLA-4) pathway (abatacept)(NCT02078882), sphingosine-1-phosphate signalling (etrasimod), or blockade of CD40/CD40L (FFP104) (NCT03155932), but final results are not available yet. Orally active Janus kinase (JAK) inhibitors are well-tolerated and have shown promise in a number of extrahepatic autoimmune diseases. They represent an interesting potential therapeutic approach. A randomised, placebo-controlled study evaluating the efficacy and safety of baricitinib (LY3009104) is planned (NTCP 03742973).
Anti-cholestatic agents
Non-fibrate PPAR agonists Beside fibrates, other PPAR agonists are under evaluation in PBC. Seladelpar is a selective PPAR-δ agonist. Whereas PPAR-α liver expression is mainly restricted to hepatocytes, PPAR-δ is expressed not only in hepatocytes but also in cholangiocytes, Kupffer cells and hepatic stellate cells. Antiinflammatory and antifibrotic effects of PPAR-δ activation have been demonstrated in a mouse model. A placebo-controlled study of 41 patients with UDCA non-responsive PBC was stopped because 3 patients developed significant but selflimiting increases in aminotransferase levels, up to 20x the ULN in patients treated with the highest dose (200 mg/d). 71 Significant decreases in ALP were observed in patients treated with seladelpar; interestingly, the 5 patients who received the intended 12-week course normalised ALP. In a recent randomised, dose ranging phase II study (5-10 mg vs. 10 mg/d) (NCT02955602), the mean decrease in ALP was similar in both groups at 52 weeks (-47% and -46%, respectively) with normalisation in a quarter of patients; the intensity of pruritus decreased and there was no aminotransferase safety signal. 72 A phase III study has been initiated. Elafibranor is a dual PPAR-α and PPAR-δ agonist that has shown promise in non-alcoholic steatohepatitis. A recent 12-week phase II study of this drug in non-cirrhotic patients with PBC and inadequate response to UDCA has shown beneficial effects on biochemical features of cholestasis and on pruritus, which make it a promising novel treatment candidate. 77 As a result, TGR5 agonists are potential candidates for the treatment of PBC despite expected off-target effects, such as inhibition of gallbladder contractibility, promotion of cell proliferation and suspected involvement in pruritus, which require consideration. However, no trials of pure TGR5 agonists are currently recruiting.
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Norursodeoxycholic acid
NorUDCA is the C23 homologue of UDCA; norUDCA lacks 1 methylene group in its side chain, which confers a relative resistance to amidation. This side chain structure determines unique physiologic and pharmacologic properties including the ability to undergo cholehepatic shunting (instead of a full enterohepatic cycle) and to stimulate cholangiocyte secretion, which results in a bicarbonate-rich hypercholeresis leading to flushing of bile ducts and reinforcement of the protective biliary bicarbonate umbrella. In addition, antifibrotic and antiinflammatory effects have been demonstrated. A large phase II, double-blind, randomised, placebocontrolled study evaluating the safety and efficacy of norUDCA for 12 weeks in patients with primary sclerosing cholangitis showed a significant biochemical improvement together with a good safety profile. 78 Because of its properties, norUDCA warrants evaluation in patients with PBC, but no clinical trial is planned to date.
Ileal bile acid transporter inhibitors
The main goal of ileal bile acid transporter (IBAT) inhibitors is to improve pruritus by decreasing retained circulating bile acids that have been proposed as key players in the mechanisms of pruritus. Several compounds altering ileal reabsorption of bile acids (apical sodium-dependent bile acid transporter inhibitors) have been developed. Lopixibat was ineffective in reducing patientreported pruritus scores (despite decreased serum bile acid levels) over a 12-week period. 79 However, GSK2330672 showed efficacy on pruritus in a randomised, double-blind, placebo-controlled, cross-over, phase II study, without evidence of improved biochemical cholestasis over a 14-day period of time. 80 Diarrhoea is the most common adverse effect and might limit the long-term use of IBAT inhibitors. A dose response study of GSK2330672 is in progress (NCT02966834).
Antifibrotic agents
Surprisingly, in contrast with other chronic liver diseases, very few clinical trials in PBC have tested agents targeting mainly fibrosis, such as inhibitors of integrin αVβ6 and lysyl oxidase homologue 2 (LOXL2). One exception is pentoxiphylline, a methylxantine derivative with potential antifibrotic properties, which has been tested. However, results are not currently available. A dual inhibitor of NADPH oxidases (NOX) 1 and NOX4 (GKT13783) is being tested in PBC because of its anti-inflammatory and antifibrotic effects. Promising results of a phase II study have recently been reported and a phase III study is planned. 81 Other speculative future developments Real hope may also be based on manipulation of microbiome, 82 
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